Skip to content

Prevention and treatment of chemotherapy-induced diarrhea with berberine in colorectal cancer patients: a randomized, double-blind controlled study

Prevention and treatment of chemotherapy-induced diarrhea with berberine in colorectal cancer patients: a randomized, double-blind controlled study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078353
Enrollment
Unknown
Registered
2023-12-06
Start date
2023-12-06
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced diarrhea

Interventions

Berberine group:Oral Berberine
Placebo group:Oral placebo

Sponsors

The Second Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with high-risk stage III and stage IV colorectal cancer who are expected to successfully complete a 6-month chemotherapy regimen. Eligible chemotherapy regimens included FOLFIRI, FOLFOX, XELOX, FOLFOXIRI, mXELIRI and CapIRI. (2) Age 18 to 80 years. (3) ECOG score =1. (4) Patients have good compliance and voluntarily receive follow-up, treatment, laboratory tests and other research steps as planned. (5) Patients or family members can understand the research plan and are willing to participate in the study, and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: (1) Taking non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and probiotics on a regular basis. (2) IBD; pelvic radiation concurrent with chemotherapy; without a functioning rectum after surgeries. (3) Severe heart, liver or kidney disease; with a history of other malignancies. (4) Psychiatric patients and patients who are unable to communicate verbally. (5) Patients who are allergic or intolerant to the berberine. (6) Female patients who are pregnant, breastfeeding, planning a pregnancy. (7) Severe constipation.

Design outcomes

Primary

MeasureTime frame
Incidence of CID from 1 to 6 months (grade =3);

Secondary

MeasureTime frame
Incidence of CID from 1 to 6 months (grades 1, 2);Drug use from 1 to 6 months;Number of chemotherapy delays and dose reductions from 1 to 6 months;Adverse event rate;PFS (Progression-Free Survival);ORR (Objective Remission Rate);DCR (Disease Control Rate);TTP (Time To Progress);Gut microbiota;fecal metabolites;Cytokine;

Countries

China

Contacts

Public ContactQinghua Yao

The Second Affiliated Hospital of Zhejiang Chinese Medical University

danfer1001@163.com+86 135 8889 9111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026